Patents Represented by Attorney Anastasia P. Winslow
-
Patent number: 7858639Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein A, B, R1, R2, R3 and R8 are described herein.Type: GrantFiled: October 30, 2009Date of Patent: December 28, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Chongqing Sun, Yanting Huang, Doree F. Sitkoff, Taekyu Lee, William R. Ewing
-
Patent number: 7816357Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I. including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R4, R5, m and n are described herein.Type: GrantFiled: December 17, 2004Date of Patent: October 19, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Guixue Yu, William R. Ewing, Amarendra B. Mikkilineni, Annapurna Pendri, Bruce A. Ellsworth, Philip M. Sher, Samuel Gerritz, Chongqing Sun, Natesan Murugesan, Ximao Wu
-
Patent number: 7595300Abstract: 15-fluoroketolides of the formula having improved activity and safety, compositions comprising them, and methods for their preparation and use in the treatment of bacterial infections.Type: GrantFiled: December 7, 2006Date of Patent: September 29, 2009Assignee: Kosan Biosciences IncorporatedInventors: Simon James Shaw, Gary W Ashley, Mark A. Burlingame
-
Patent number: 7501416Abstract: The present invention generally relates to quinoxaline compounds having Formula 1 or Formula 2 wherein the variables are as defined herein, and methods of using them.Type: GrantFiled: February 1, 2005Date of Patent: March 10, 2009Assignee: Bristol-Myers Squibb CompanyInventor: Kyoung S. Kim
-
Patent number: 7459294Abstract: During the production of a product compound by fermentation, the concentration of a precursor compound is maintained within a pre-selected concentration range by having an adsorbent resin in contact with the culture medium. The adsorbent resin reversibly adsorbs precursor compound and, as un-adsorbed precursor compound is converted to product compound, adsorbed precursor compound is released from the resin, thus maintaining the concentration of precursor compound within the pre-selected range.Type: GrantFiled: August 6, 2004Date of Patent: December 2, 2008Assignee: Kosan Biosciences IncorporatedInventors: Timothy A. Leaf, Ruchir P. Desai, Peter Licari, Elaine Jennifer Woo
-
Patent number: 7388009Abstract: Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R6, X and Z are as described in the specification.Type: GrantFiled: October 3, 2003Date of Patent: June 17, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Katerina Leftheris, Stephen T. Wrobleski, Alaric J. Dyckman
-
Patent number: 7342034Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.Type: GrantFiled: September 21, 2005Date of Patent: March 11, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Mark E. Salvati, James Aaron Balog
-
Patent number: 7314876Abstract: Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are surprisingly advantageous as p38 kinase inhibitors, wherein R3 is hydrogen, methyl, perfluoromethyl, methoxy, halogen, cyano, NH2, or NH(CH3), preferably methyl; X is N or CH; and R1 through R6 are as described in the specification.Type: GrantFiled: April 22, 2003Date of Patent: January 1, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Katerina Leftheris, John Hynes, Arthur M P. Doweyko
-
Patent number: 7312237Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.Type: GrantFiled: March 5, 2002Date of Patent: December 25, 2007Assignee: Bristol-Myers Squibb Co.Inventor: Francis Y. F. Lee
-
Patent number: 7241755Abstract: The present invention relates to compounds of the formula in which the variables G, W, Q, X, Y, B1, B2, Z1, Z2, and R1–R7 are as defined herein, methods for the preparation of the derivatives and intermediates thereof.Type: GrantFiled: August 30, 2006Date of Patent: July 10, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Gregory D. Vite, Soong-Hoon Kim, Robert M. Borzilleri, James A. Johnson
-
Patent number: 7211593Abstract: The present invention relates to compounds useful in the treatment of cancer or other proliferative diseases represented by the formula wherein: R1, R2, R3, R4, R5 are hydrogen or lower alkyl; R6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or heterocyclo; X is hydrogen and Y is hydroxy, or X and Y taken together represent a carbon-carbon bond; and pharmaceutically acceptable salts, solvates, or hydrates thereof. Also included are therapeutic compositions containing the compounds represented by formula I as active ingredients, alone or in combination with other therapeutic agents useful in the treatment of cancer or other proliferative diseases.Type: GrantFiled: March 11, 2003Date of Patent: May 1, 2007Assignee: Bristol-Myers Squibb Co.Inventors: Gregory D. Vite, Alicia Regueiro-Ren
-
Patent number: 7157595Abstract: According to one embodiment the invention concerns a process for a degradation of an epothilone C or a epothilone D, wherein an epothilone C or epothilone D is subjected to an olefin metathesis in the presence of ethylene and subsequently an optional ester hydrolysis.Type: GrantFiled: February 27, 2002Date of Patent: January 2, 2007Assignee: Helmholtz-Zentrum fur Infektionsforschung GmbHInventors: Gerherd Hoefle, Usama Karama
-
Patent number: 7041692Abstract: Methods of treating Factor VIIa-associated conditions in a mammal are described, comprising administering to the mammal in need of treatment thereof an effective amount of at least one compound having the formula (I), or a pharmaceutically-acceptable salt, hydrate or prodrug thereof.Type: GrantFiled: June 17, 2003Date of Patent: May 9, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Timothy Herpin, Gregory S. Bisacchi, Zulan Pi, E. Scott Priestley, T. G. Murali Dhar
-
Patent number: 7022330Abstract: A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous ethanol and a suitable nonionic surfactant in a second vial. All steps are carried out with protection from light. In use, the contents of the second or diluent vial are added to the lyophilized product and mixed to constitute the epothilone analog and the resulting solution is diluted with a suitable diluent to produce a solution for intravenous injection containing the epothilone analog in a concentration of from about 0.1 mg/mL to about 0.9 mg/mL. A preferred surfactant is polyethoxylated castor oil and a preferred diluent is Lactated Ringer's Injection.Type: GrantFiled: January 17, 2002Date of Patent: April 4, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia
-
Patent number: 7008936Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative diseases.Type: GrantFiled: June 12, 2003Date of Patent: March 7, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Maurizio Voi, David Lebwohl
-
Patent number: RE39251Abstract: There are provided in accordance with the present invention two crystalline polymorphs, designated Form A and Form B, respectively, as well as mixtures thereof, of an epothilone analog represented by the formula Also provided are methods of forming the novel polymorphs, therapeutic methods utilizing them and pharmaceutical dosage forms containing them.Type: GrantFiled: March 9, 2005Date of Patent: August 29, 2006Assignee: Bristol-Myers Squibb Co.Inventor: Zhenrong Guo
-
Patent number: RE39356Abstract: The present invention relates to a process for the preparation of epothilone analogs by initially forming novel ring-opened epothilones and carrying out a macrolactamization reaction thereon. The subject process is amenable to being carried out in a single reaction vessel without isolation of the intermediate compound and provides at least about a three-fold increase in yield over prior processes for preparing the desired epothilone analogs.Type: GrantFiled: February 11, 2005Date of Patent: October 17, 2006Assignee: Bristol-Myers Squibb Co.Inventors: Wen Sen Li, John E. Thornton, Zhenrong Guo, Shankar Swaminathan, Robert M. Borzilleri, Soong-Hoon Kim, Denis Favreau
-
Patent number: RE41393Abstract: Methods of treating tumors in a mammal, especially a human that has demonstrated resistance to other chemotherapeutic agents, is disclosed. Specifically, methods of the present invention are effective in tumors that have initially been unresponsive to taxane therapy, or have developed resistance during the course of treatment. The methods of the present invention comprise administering epothilone derivatives selected from those represented by the formula: The subject epothilone derivatives are advantageous in addition to their enhanced potency and effectiveness against tumors that have demonstrated resistance to therapy with taxane oncology agents in that they are efficacious upon oral administration.Type: GrantFiled: February 2, 2006Date of Patent: June 22, 2010Assignee: Bristol-Myers Squibb CompanyInventor: Francis Y.F. Lee
-
Patent number: RE42191Abstract: The present invention relates to improved methods for the production, isolation and purification of epothilone B. These methods include, for example, a fermentation process for the production of epothilone B, isolation via adsorption onto a resin, and subsequent purification.Type: GrantFiled: August 6, 2009Date of Patent: March 1, 2011Assignee: Bristol-Myers Squibb CompanyInventors: Daniel Benigni, Thomas P. Tully, Brian L. Davis
-
Patent number: RE43003Abstract: The present invention relates to compounds of the formula in which the variables G, W, Q, X, Y, B1, B2, Z1, Z2, and R1–R7 are as defined herein, methods for the preparation of the derivatives and intermediates thereof.Type: GrantFiled: September 15, 2010Date of Patent: December 6, 2011Assignee: Bristol-Myers Squibb CompanyInventors: Gregory D. Vite, Soong-Hoon Kim, James A. Johnson